25 Norman Way
Over
Cambridge CB24 5QE
United Kingdom
44 1223 967 943
https://www.4basebio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 84
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Heikki Lanckriet Ph.D. | CEO, Chief Scientific Officer & Executive Director | 441.2k | N/D | 1977 |
Mr. David Roth | CFO, Company Secretary & Executive Director | 317.9k | N/D | 1967 |
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
La calificación ISS Governance QuickScore de 4basebio PLC a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.